Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series

Related Experiment Video

Updated: Nov 5, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Anthony S Zembillas1, Stefanie M Thomas2, Seth J Rotz2

  • 1Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.

Pediatric Hematology and Oncology
|May 18, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.2K
Intralymphatic Immunotherapy and Vaccination in Mice07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.6K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
905